Osborne Partners Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Osborne Partners Capital Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,200	Closed	-$226K	–	174
2015 Q2	$226K	Sell	3,200 -600	-16%	-$43.2K	0.03%	170
2015 Q1	$267K	Hold	3,800	–	–	0.04%	164
2014 Q4	$244K	Hold	3,800	–	–	0.03%	169
2014 Q3	$242K	Hold	3,800	–	–	0.03%	165
2014 Q2	$236K	Hold	3,800	–	–	0.03%	163
2014 Q1	$222K	Sell	3,800 -400	-10%	-$22.6K	0.03%	173
2013 Q4	$223K	Sell	4,200 -200	-5%	-$10.1K	0.03%	172
2013 Q3	$210K	Hold	4,400	–	–	0.03%	169
2013 Q2	$200K	Buy	+4,400	New	+$203K	0.03%	168

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

MIM

Macroview Investment Management Bethesda, Maryland $144M AUM 19.29% 1-Year Est. Return

AHS

Aspiriant Holdings S3 Los Angeles, California $233M AUM 3.13% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Osborne Partners Capital Management's PPH Position: Q3 2015 in Review

Osborne Partners Capital Management sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2015, closing a stake of 3,200 shares — an estimated $226K sold.

Osborne Partners Capital Management first reported a position in PPH in Q2 2013 and held it in 9 quarters. The position peaked at $267K in Q1 2015. 60 funds tracked by Wall St. Rank hold PPH as of Q3 2015.

Osborne Partners Capital Management reported no remaining VanEck Pharmaceutical ETF position as of Q3 2015 after selling out during the quarter.
Osborne Partners Capital Management sold 3,200 VanEck Pharmaceutical ETF shares in Q3 2015, an estimated $226K.
Osborne Partners Capital Management first reported a position in VanEck Pharmaceutical ETF in Q2 2013 and held it in 9 quarters.
Osborne Partners Capital Management's VanEck Pharmaceutical ETF position peaked at $267K in Q1 2015.
60 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2015.

Based on Osborne Partners Capital Management's 13F filing for Q3 2015, filed 16 Oct 2015.